These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

295 related items for PubMed ID: 24002407

  • 1. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
    [Abstract] [Full Text] [Related]

  • 2. Insulin-sensitisers in the treatment of polycystic ovary syndrome.
    Teede HJ, Meyer C, Norman RJ.
    Expert Opin Pharmacother; 2005 Nov; 6(14):2419-27. PubMed ID: 16259573
    [Abstract] [Full Text] [Related]

  • 3. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
    Brettenthaler N, De Geyter C, Huber PR, Keller U.
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3835-40. PubMed ID: 15292314
    [Abstract] [Full Text] [Related]

  • 4. Insulin resistance and metformin in polycystic ovary syndrome.
    Ben-Haroush A, Yogev Y, Fisch B.
    Eur J Obstet Gynecol Reprod Biol; 2004 Aug 10; 115(2):125-33. PubMed ID: 15262344
    [Abstract] [Full Text] [Related]

  • 5. The role of metformin in the treatment of polycystic ovary syndrome (PCOS).
    Wang HS.
    Chang Gung Med J; 2006 Aug 10; 29(5):445-7. PubMed ID: 17214387
    [Abstract] [Full Text] [Related]

  • 6. Thiazolidinediones for treatment of polycystic ovary syndrome.
    Stout DL, Fugate SE.
    Pharmacotherapy; 2005 Feb 10; 25(2):244-52. PubMed ID: 15767238
    [Abstract] [Full Text] [Related]

  • 7. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
    Katsiki N, Hatzitolios AI.
    Curr Opin Obstet Gynecol; 2010 Dec 10; 22(6):466-76. PubMed ID: 20724929
    [Abstract] [Full Text] [Related]

  • 8. Metabolic and other effects of pioglitazone as an add-on therapy to metformin in the treatment of polycystic ovary syndrome (PCOS).
    Valsamakis G, Lois K, Kumar S, Mastorakos G.
    Hormones (Athens); 2013 Dec 10; 12(3):363-78. PubMed ID: 24121378
    [Abstract] [Full Text] [Related]

  • 9. Insulin and oral antidiabetic agents for treatment of polycystic ovary syndrome.
    Kuscu NK, Koyuncu FM.
    Medscape Womens Health; 2002 Dec 10; 7(5):3. PubMed ID: 12466732
    [Abstract] [Full Text] [Related]

  • 10. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia.
    Genazzani AD, Lanzoni C, Ricchieri F, Baraldi E, Casarosa E, Jasonni VM.
    Gynecol Endocrinol; 2007 Mar 10; 23(3):146-52. PubMed ID: 17454168
    [Abstract] [Full Text] [Related]

  • 11. Two weeks of metformin improves clomiphene citrate-induced ovulation and metabolic profiles in women with polycystic ovary syndrome.
    Khorram O, Helliwell JP, Katz S, Bonpane CM, Jaramillo L.
    Fertil Steril; 2006 May 10; 85(5):1448-51. PubMed ID: 16579997
    [Abstract] [Full Text] [Related]

  • 12. Insulin-sensitizing agents in polycystic ovary syndrome.
    Pasquali R, Gambineri A.
    Eur J Endocrinol; 2006 Jun 10; 154(6):763-75. PubMed ID: 16728533
    [Abstract] [Full Text] [Related]

  • 13. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome.
    Cho LW, Kilpatrick ES, Keevil BG, Coady AM, Atkin SL.
    Clin Endocrinol (Oxf); 2009 Feb 10; 70(2):233-7. PubMed ID: 18547343
    [Abstract] [Full Text] [Related]

  • 14. Insulin resistance in polycystic ovarian disease.
    Bhatia V.
    South Med J; 2005 Sep 10; 98(9):903-10; quiz 911-2, 923. PubMed ID: 16217983
    [Abstract] [Full Text] [Related]

  • 15. [Polycystic ovary syndrome. New pathophysiological discoveries--therapeutic consequences].
    Svendsen PF, Nilas L, Nørgaard K, Madsbad S.
    Ugeskr Laeger; 2005 Aug 22; 167(34):3147-51. PubMed ID: 16117910
    [Abstract] [Full Text] [Related]

  • 16. Use of metformin in polycystic ovary syndrome.
    Mathur R, Alexander CJ, Yano J, Trivax B, Azziz R.
    Am J Obstet Gynecol; 2008 Dec 22; 199(6):596-609. PubMed ID: 19084097
    [Abstract] [Full Text] [Related]

  • 17. Medical therapy in women with polycystic ovarian syndrome before and during pregnancy and lactation.
    Goldenberg N, Glueck C.
    Minerva Ginecol; 2008 Feb 22; 60(1):63-75. PubMed ID: 18277353
    [Abstract] [Full Text] [Related]

  • 18. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
    Dunaif A.
    Nat Clin Pract Endocrinol Metab; 2008 May 22; 4(5):272-83. PubMed ID: 18364705
    [Abstract] [Full Text] [Related]

  • 19. Endocrine-metabolic effects of the treatment with pioglitazone in obese patients with polycystic ovary syndrome.
    Garmes HM, Tambascia MA, Zantut-Wittmann DE.
    Gynecol Endocrinol; 2005 Dec 22; 21(6):317-23. PubMed ID: 16390779
    [Abstract] [Full Text] [Related]

  • 20. Insulin-lowering agents in the management of polycystic ovary syndrome.
    De Leo V, la Marca A, Petraglia F.
    Endocr Rev; 2003 Oct 22; 24(5):633-67. PubMed ID: 14570747
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.